Paasa Logo
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. logo
3378HKSEMarket closedOpens 9:30am HKT

Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

HK$28.06Last updated
+HK$0.06 (0.21%)Past day
Timezone

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKSE: 3378) is trading at HK$28.06, about ₹344 at today's HKD/INR rate, as of 25 Sep 2026, 4:08 AM ET, up 0.21% today. Indian residents can buy Hanx Biopharmaceuticals (Wuhan) from India on Paasa under the RBI's Liberalised Remittance Scheme.

Quote

Open:HK$27.02
Previous close:HK$28.00
Volume:1.90K

Today's low

HK$27.02

Today's high

HK$28.06

52 week low

HK$13.48

52 week high

HK$33.80

3378 opened at HK$27.02, closed previously at HK$28.00, and has traded between HK$13.48 and HK$33.80 over the past 52 weeks.

About

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and development of immune-oncology therapies. The company's product pipeline includes HX009, a bifunctional anti-PD-1/SIRPa fusion protein that is in Phase IIa clinical trials for the treatment of EBV+ non-Hodgkin lymphoma, acral/mucosal subtype melanoma, relapsed/refractory melanoma post-PD-1 therapy, and Biliary tract cancer; HX044, a CTLA-4/SIRPa bifunctional fusion protein which is in Phase Ia for the treatment of solid tumours; HX301, a novel oral multi-kinase inhibitor that is in Phase IIa for the treatment of glioblastoma; and HX111, an ADC drug candidate to treat solid tumours. It is also developing proprietary in-house platforms, such as the VersatiBody, a multi-functional antibody discovery platform that generated two clinical-stage FIC bifunctional fusion proteins (HX009, HX044), as well as completed the preclinical development of multiple ADC/bispecific molecules, including FIC PPC HX111 (OX40-ADC) and HX116 (PD-L1×VEGF BsAb-ADC); and the autoRx40, an autoimmune therapeutic platform, completing the design of multiple candidate molecules in the field of autoimmune diseases, such as HX035, HX038, and HX138. Hanx Biopharmaceuticals (Wuhan) Co., Ltd. was incorporated in 2014 and is headquartered in Wuhan, China.

Country
CN
CEO
Qixiang Li
Exchange listed on
HKSE
Industry
Biotechnology
Base currency
HKD
Full Time Employees
60
Sector
Healthcare
IPO date
23/12/2025

Key statistics

Avg. volume

62.00K

Market cap

HK$3.76B

P/E Ratio

85.62

Price-to-sales ratio

0.13

Enterprise value

CN¥12.22B

Free cash flow yield

59.79%

Debt-to-equity ratio

2.04

Return on equity

13.13%

ROIC

4.06%

Beta

-1.14

Dividend yield

0.00%

Last dividend

HK$0.00

Financial overview

Revenue

CN¥25.69B

Earnings per share

CN¥0.28

Free cash flow

CN¥1.92B

Net profit margin

2.99%

Gross margin

5.35%

EBITDA

CN¥1.29B

Revenue growth

45.21%

Similar securities

This is not an investment recommendation

How to buy Hanx Biopharmaceuticals (Wuhan) from India

Indian residents can buy Hanx Biopharmaceuticals (Wuhan) shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.

  1. Open a Paasa account

    Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.

  2. Add funds under LRS

    Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.

  3. Search for Hanx Biopharmaceuticals (Wuhan) and place an order

    Find Hanx Biopharmaceuticals (Wuhan) by name or by its ticker, 3378, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. Hanx Biopharmaceuticals (Wuhan) trades 7:00 am – 1:30 pm IST; orders can only execute during that window.

  4. Track holdings and download tax reports

    Follow your Hanx Biopharmaceuticals (Wuhan) position in HKD and INR. Hanx Biopharmaceuticals (Wuhan) pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.

Read the full guide: how to invest in Hanx Biopharmaceuticals (Wuhan) from India

Trading and taxes when buying Hanx Biopharmaceuticals (Wuhan) from India

Trading and limits

Trading hours
9:30 am – 4:00 pm HKT
LRS limit
$250,000Per financial year, under the RBI's Liberalised Remittance Scheme.

Tax for Indian residents

TCS on remittance
20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
Capital gains in India
12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
Dividends
NoneHanx Biopharmaceuticals (Wuhan) does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained

Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.

FAQs

Can Indian residents buy Hanx Biopharmaceuticals (Wuhan) stock?

Yes. Hanx Biopharmaceuticals (Wuhan) (3378) has been listed on the Hong Kong Stock Exchange since 2025, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.

How much does one Hanx Biopharmaceuticals (Wuhan) share cost in rupees?

One Hanx Biopharmaceuticals (Wuhan) share is HK$28.06 — about ₹344 at an HKD/INR rate of 12.25 on 24 Sep 2026. Both the Hanx Biopharmaceuticals (Wuhan) price and the rupee rate move during the day, so the rupee cost changes with them.

What are the LRS and TCS rules for buying Hanx Biopharmaceuticals (Wuhan) from India?

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.

What is the minimum I can buy of Hanx Biopharmaceuticals (Wuhan)?

Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.

How are gains on Hanx Biopharmaceuticals (Wuhan) shares taxed in India?

Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Hanx Biopharmaceuticals (Wuhan) price. Paasa issues a capital-gains statement for your return.

Does Hanx Biopharmaceuticals (Wuhan) pay a dividend?

No. Hanx Biopharmaceuticals (Wuhan) does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.

When can I trade Hanx Biopharmaceuticals (Wuhan) from India?

The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.

Is Hanx Biopharmaceuticals (Wuhan) a Hong Kong SAR China company, and does that change how it is taxed?

Hanx Biopharmaceuticals (Wuhan) trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. Hanx Biopharmaceuticals (Wuhan) trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.

Do I have to declare Hanx Biopharmaceuticals (Wuhan) shares in my Indian tax return?

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Hanx Biopharmaceuticals (Wuhan) holding, its cost and its closing value.

How do I sell Hanx Biopharmaceuticals (Wuhan) and bring the money back to India?

You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.